Moors & Cabot Inc. Decreases Stake in Sanofi (NASDAQ:SNY)

Moors & Cabot Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,835 shares of the company’s stock after selling 453 shares during the quarter. Moors & Cabot Inc.’s holdings in Sanofi were worth $452,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of SNY. POM Investment Strategies LLC purchased a new stake in Sanofi in the 2nd quarter valued at $25,000. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the 3rd quarter worth $29,000. Concord Wealth Partners boosted its position in shares of Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after acquiring an additional 363 shares during the last quarter. Arrow Financial Corp purchased a new stake in shares of Sanofi in the second quarter valued at about $35,000. Finally, Fortitude Family Office LLC increased its position in Sanofi by 708.6% during the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares during the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SNY has been the subject of several analyst reports. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Performance

NASDAQ:SNY opened at $48.28 on Friday. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The company has a 50 day moving average price of $53.70 and a 200 day moving average price of $52.15. The stock has a market capitalization of $122.53 billion, a P/E ratio of 24.63, a PEG ratio of 1.22 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period last year, the business posted $2.55 earnings per share. Equities research analysts forecast that Sanofi will post 4.29 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.